From WikiProjectMed
Jump to navigation Jump to search
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Trade namesTelura
Other namesEFV/3TC/TDF
Clinical data
Routes of
By mouth
Defined daily dosenot established[1]

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed-dose combination medication for the treatment of HIV/AIDS.[2] It combines efavirenz, lamivudine, and tenofovir disoproxil.[2] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[3] It is taken by mouth.[2]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[2] Severe side effects may include depression, psychosis, or osteonecrosis.[2] In those with a history of epilepsy, it may increase the frequency of seizures.[2] Greater care should also be taken in those with kidney problems.[2] It is unclear if use during pregnancy is safe.[2][4]

It is on the World Health Organization's List of Essential Medicines.[5] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[2] The combination received tentative approval in the United States in 2014.[6] Its availability and importance is supported by Medecins Sans Frontieres.[2]


The defined daily dose is not established[1]


  1. 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 11 September 2020. CS1 maint: discouraged parameter (link)
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO).
  3. World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  4. "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017. CS1 maint: discouraged parameter (link)
  5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017. CS1 maint: discouraged parameter (link)

External links